Jill Shoffner-Brown loves satisfying the customer and hearing success stories about her products.
When asked what aspects of her career keep her motivated, Jill Shoffner-Brown, a pharmaceutical sales rep for Boehringer Ingelheim Corp., replies, "I really just love my job. I love satisfying the customer and hearing success stories about my product(s)."
Shoffner-Brown considers herself a "full-service rep," meaning she takes care of everything for her physicians. "I talk to the office manager and make sure I have supplied him or her with all the information he or she may need," she said. "I leave patient-education materials if needed. I also make sure I know where the samples are so I can take inventory without having to disturb the physician."
Being a full-service rep also means understanding managed care and formularies. "Managed care is a huge part of the business," Shoffner-Brown said. "Reps need to know a physician's plans and what products are on the formularies. A rep should also find out if his or her competition's products are on the formulary, and if so, report these to his or her district manager."
Another part of being a full-service rep is understanding a physician's work.
Shoffner-Brown finds preceptorships useful for reps. "A preceptorship allows reps to increase their knowledge about diseases and human anatomy," she said. "It's like watching a case history; you can see a physician prescribe your drug and see how physicians use the information you supply them. It also builds rapport with that physician and any other attending physicians. Preceptorships make a rep really feel like a team player."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.